Iambic, an AI drug discovery specialist, banks $150M in an IPO

BioPharma DiveView source article

Part of story

Iambic Therapeutics raises $150M in IPO for AI-driven cancer pipeline

Nvidia-backed Iambic Therapeutics completed a $150 million IPO at $16 per share to advance its AI-designed cancer drugs and platform partnerships with major pharma companies.

Oct 15, 20262 sourcesAI startups Cancer treatment breakthroughs AI for developers

Iambic Therapeutics raises $150M in IPO for AI-driven cancer pipeline

Other sources for this story

Endpoints

Iambic, an AI drug discovery specialist, banks $150M in an IPO

Part of story

Iambic Therapeutics raises $150M in IPO for AI-driven cancer pipeline

Other sources for this story

Iambic snags $150M IPO for AI-driven cancer pipeline

Iambic, an AI drug discovery specialist, banks $150M in an IPO

Part of story

Iambic Therapeutics raises $150M in IPO for AI-driven cancer pipeline

Other sources for this story

Iambic snags $150M IPO for AI-driven cancer pipeline